Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Galderma receives FDA approval to market Restylane Lyft

Galderma, a global healthcare company focused on skin health, announced that it has received US Food and Drug Administration (FDA) approval to market Restylane Lyft for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21.

Restylane Lyft, formerly marketed as Perlane-L, is an injectable gel used to increase volume and smooth wrinkles in the face. With this new indication, Restylane Lyft is the first and only FDA approved filler indicated to provide fullness to the midface area (cheeks) and to correct and smooth the nasolabial folds (smile lines).

"Consumers are looking for safe, high quality products that can deliver natural-looking results. This new indication demonstrates the versatility of Restylane Lyft and its efficacy in addressing smile lines and restoring structure to the cheeks and midface area," said Kelly Huang, Ph.D., Vice President and General Manager of Galderma’s Aesthetic and Corrective Business Unit in the US."

This FDA approval marks the fifth major indication in the U.S. for the Restylane family of products. Restylane Lyft joins Restylane, indicated to correct and smooth smile lines as well as to augment the lips, and Restylane Silk, the first and only treatment that is approved for lip enhancement and the treatment of wrinkles and lines around the mouth.

These brands combined represent the broadest range of dermal fillers with the most FDA approved indications commercially available for healthcare professionals and patients.

In a clinical trial involving 200 patients, investigators observed that 88.7% of patients treated with Restylane Lyft showed an improvement in fullness in the right and left midface areas (combined) at 2 months, and more than half maintained improvement for 12 months.

Additionally, 95% of patients reported improvement with the appearance of their midface at 2 months and 73% of patients reported improvement at 12 months2. The most common adverse events observed in the trial included: tenderness, redness, bruising, swelling and itching. These events decreased in severity over time and most were resolved within 2 weeks.

The brand name is changing from Perlane-L to Restylane Lyft to help health care providers and consumers understand where the brand fits among the other Galderma products that are based on the core Restylane technology.

Dating back to 1961, Galderma is now present in 80 countries with an extensive product portfolio to treat a range of dermatological conditions.